The poor performance of the off-the-shelf approach at either the allele, gene, or genomic region scale is not surprising as even the few genetic biomarkers incorporated into the WHO classification for hematological cancer [17] are largely non-exclusive between disease subtypes and exist at relatively low percentages (with the exception of the BCR-ABL fusion in CML). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.